IDRI is working on a COVID-19 vaccine multiplier

Blog Post Image
Real Estate

Seattle’s Infectious Disease Research Institute is working with Houston’s Baylor College of Medicine to multiply the doses of a potential COVID-19 vaccine by 30 to 100 times. Other partners in the effort include Seattle-based PATH and Texas Children’s Hospital Center for Vaccine Development.

If the project proceeds as planned, Baylor and its partners could repurpose a vaccine candidate originally created to counter a different coronavirus-based disease known as severe acute respiratory syndrome, or SARS, to fight off COVID-19.

The recombinant-protein vaccine was tested against the SARS virus in preclinical trials, but because the 2002-2003 SARS epidemic faded away, the vaccine never got a chance to advance to clinical trials.

Find more information here: